NCT06059157 Epileptogenic Network Visualisation With Advanced MRI
| NCT ID | NCT06059157 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
| Condition | Drug Resistant Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-10-25 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-10-25 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to improve non-invasive identification of epileptogenic networks in drug-resistant epileptic patient. The investigators aim to compare epileptogenic network identification with stereo-EEG (used as glod standard) with the identification of the same network using advanced MRI (rs-fMRI, microstructural analysis of white matter, ...). The main goals are to: 1. Compare the accuracy of network identification. 2. Analyse the effect of the MRI sequences on candidates selection and target identification. Participants will already have been selected for stereoEEG and will undergo a supplementary MRI (about 1h) with the additional MRI sequences. Follow-up MRI are scheduled for patient undergoing a second, therapeutic epileptic surgery.
Eligibility Criteria
Inclusion Criteria: * Patient suffering from drug-resistant epilepsy * Patient already selected for SEEG implantation as part of their epileptic networks Exclusion Criteria: * Patient excluded from SEEG (pregnant women, children too young for the procedure, patient unable to undergo the procedure) * Contra-indication for MRI
Contact & Investigator
Riëm El Tahry, PhD
PRINCIPAL INVESTIGATOR
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Frequently Asked Questions
Who can join the NCT06059157 clinical trial?
This trial is open to participants of all sexes, aged 3 Years or older, studying Drug Resistant Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06059157 currently recruiting?
Yes, NCT06059157 is actively recruiting participants. Contact the research team at riem.eltahry@saintluc.uclouvain.be for enrollment information.
Where is the NCT06059157 trial being conducted?
This trial is being conducted at Brussels, Belgium.
Who is sponsoring the NCT06059157 clinical trial?
NCT06059157 is sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The principal investigator is Riëm El Tahry, PhD at Cliniques universitaires Saint-Luc- Université Catholique de Louvain. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.